Cure8 news brief
Changes that let people start biologic induction at home can reduce clinic visits and make starting treatment easier. Patients on or considering risankizumab for Crohn’s may be affected by this administration update.
Adults with Crohn’s disease considering or using Skyrizi (risankizumab), gastroenterology clinicians, infusion/infusion-alternative program coordinators, and patient advocates focused on access and convenience.
The item in this briefing flags a US FDA approval change that allows Skyrizi to be induced subcutaneously at home for Crohn’s disease, which relates to how the medicine is administered rather than a new drug approval. If you or someone you care for uses biologic therapy for Crohn’s, this could affect where and how induction dosing is given.
It appears in a roundup of regulatory news alongside other FDA and industry updates; the brief does not provide full label details, eligibility, or timing for implementation. For specific dosing schedules, safety information, and whether this option applies to an individual patient, consult the formal FDA label update or discuss with the treating clinician.
The source is Regulatory Affairs Professional Society (RAPS) Regulatory Recon weekly briefing, summarizing multiple regulatory items drawn from other reporting outlets.
This item is from a regulatory news roundup and cites secondary reporting; it does not include the FDA label text or detailed eligibility criteria. Confirm details from the FDA approval announcement or product labeling before making treatment decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Market and late-stage trial updates can indicate which new therapies may become available and influence treatment options, access, and research priorities for Crohn's disease over the coming years.
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...
An at-home subcutaneous induction option for risankizumab could make starting Skyrizi easier and more convenient for adults with moderate-to-severe Crohn’s disease, potentially reducing the need for clinic infusions.
